medigraphic.com

2008, Number S2

<< Back Next >>

Arch Cardiol Mex 2008; 78 (S2)

Prevention and treatment of hypertension and coronary heart disease

Mendoza-González C, Rosas M, Lomelí EC, Lorenzo JA, Méndez A, Martínez-Reding J, Martínez-Sánchez C, Pastelín G, Férez-Santander SM, Attie F

Language: Spanish
References: 90
Page: 58-73
PDF size: 174.83 Kb.


ABSTRACT

The association between arterial systemic hypertension arterial coronary disease has been demonstrated by cumulated evidence of several epidemiological studies. Hypertension is an important independent risk factor for the development of coronary artery disease, vascular cerebral disease and nephropathy. Important advances exist in the knowledge of neurohumoral and hemodynamic factors that come together in the pathophysiology of the hypertension and in the development of coronary disease that allow to establish better strategies not only of treatment, but also of prevention, with the purpose of diminishing the cardiovascular mortality. The spectrum of the coronary artery disease secondary to atherosclerosis is wide and the strategies of treatment of hypertension must be adapted to each particular case. The treatment of both conditions needs of specific limits of agreement to the conditions of the patient and the form of presentation of each one of these disease.


REFERENCES

  1. Rosendorff C, Black HR, Cannon CP, et al: Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. A Scientific Statement from the American Heart Association Council for High Blood Pressure Research and the Councils on clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.

  2. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.

  3. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, Levy D: Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003-1010.

  4. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.

  5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 361: 1060.

  6. Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P: Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161: 1501-1508.

  7. Yusuf S: Preventing vascular events due to elevated blood pressure. Circulation 2006; 113: 2166-2168.

  8. Kannel WB: Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976; 37: 269-285.

  9. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(Suppl 1): S1-S246.

  10. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26(Suppl 1): S80-S82.

  11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-3421.

  12. Franklin SS, Gustin W IV, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D: Hemodynamic patterns of age-related changes in blood pressure. Circulation 1997; 96: 308-315.

  13. Oparil S, Zaman MA, Calhoun DA: Pathogenesis of hypertension. Ann Intern Med 2003; 139: 761-776.

  14. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23: S9-S17.

  15. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.

  16. Schiffrin EL: Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318.

  17. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.

  18. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A: Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-172.

  19. Cai H, Griendling KK, Harrison DG: The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-478.

  20. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478.

  21. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA: Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004; 110: 3849-3857.

  22. Singh BM, Mehta JL: Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003; 163: 1296-1304.

  23. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.

  24. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE: Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48: 833-838.

  25. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.

  26. Canty JM Jr: Coronary pressure-function and steady-state pressure-flow relations during autoregulation in the unanesthetized dog. Circ Res 1988; 63: 821-836.

  27. Hoffman JI: Heterogeneity of myocardial blood flow. Basic Res Cardiol 1995; 90: 103-111.

  28. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.

  29. Wang JG, Staessen JA: Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens (Greenwich). 2003; 5: 66-75.

  30. Staessen JA, Wang J-G, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.

  31. Rosendorff C: Ischemic heart disease in hypertension. In: Black HR, Elliott WJ, eds. Hypertension: A Companion to Braunwald’s Heart Disease. Philadelphia, Pa: Saunders Elsevier; 2007: 327-339.

  32. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.

  33. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.

  34. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension I. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143-1152.

  35. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985; 291: 97-104.

  36. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA 1991; 265: 3255-3264.

  37. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.

  38. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907.

  39. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.

  40. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.

  41. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.

  42. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213-1225.

  43. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.

  44. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published correction appears in N Engl J Med 1992; 327: 685-691.

  45. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 1993; 329: 1456-1462.

  46. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.

  47. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: E28 -E32.

  48. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.

  49. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2004; 350: 203.

  50. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.

  51. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med 2003; 348: 2271. 1321.

  52. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.

  53. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE: Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.

  54. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S; the Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52-60.

  55. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O’Rourke RA, Pasternak RC, Williams SV; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina): ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159-168.

  56. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) [published correction appears in Circulation. 2005;111:2013]. Circulation 2004; 110: 588-636.

  57. Rosendorff C: Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opin Pharmacother 2003; 4: 1535-1541.

  58. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.

  59. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002; 165: 191-199.

  60. Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-1535.

  61. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study. N Engl J Med 2000; 342: 1376.

  62. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC; for the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-677.

  63. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL: PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.

  64. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ: Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592.

  65. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautnar B, Corbalan R, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835- 842.

  66. Theroux P, Cairns JA. Acute non-ST-segment elevation coronary syndromes: unstable angina and non-ST-segment elevation myocardial infarction. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence-Based Cardiology. 2nd ed. London, UK: BMJ Books; 2003: 397-425.

  67. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) 2002. Braunwald et al. 2002 ACC/AHA Practice Guidelines. www.acc.org

  68. Andrus MR, Holloway KP, Clark DB: Use of beta-blockers in patients with COPD. Ann Pharmacother 2004; 38: 142-145.

  69. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4: CD003566.

  70. Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen-Bjergaard O, Mortensen LS; Danish Verapamil Infarction Trial (DAVIT) Study Group. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997; 79: 738-741.

  71. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE: Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423- 429.

  72. Boden WE, Krone RJ, Kleiger RE, Oakes D, Greenberg H, Dwyer EJ Jr, Miller JP, Abrams J, Coromilas J, Goldstein R; for the Multicenter Diltiazem Post-Infarction Trial Research Group: Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction. Am J Cardiol 1991; 67: 335-342.

  73. Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM: Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Am J Cardiol 1996; 77: 16D-21D.

  74. Theroux P, Gregoire J, Chin C, Pelletier G, de Guise P, Juneau M: Intravenous diltiazem in acute myocardial infarction: Diltiazem as Adjunctive Therapy to Activase (DATA) trial. J Am Coll Cardiol 1998; 32: 620-628.

  75. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA; Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003; 163: 2345-2353.

  76. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico: GISSI-3: effects of lisinopri1 and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.

  77. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.

  78. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease, 1: treatments following myocardial infarction. JAMA 1988; 260: 2088-2093.

  79. Brand DA, Newcomer LN, Freiburger A, Tian H: Cardiologists’ practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995; 26: 1432-1436.

  80. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E: Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422-437.

  81. First International Study of Infarct Survival Collaborative Group: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-I. Lancet 1986; 2: 57-66.

  82. Flather M, Pipilis A, Collins R, Budaj A, Hargreaves A, Kolettis T, Jacob A, Millane T, Fitzgerald L, Cedro K; ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. Eur Heart J 1994; 15: 608-619.

  83. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo controlled trial. Lancet 2005; 366: 1622-1632.

  84. Braunwald E, Pfeffer MA: Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991; 68: 1D-6D.

  85. Kim CB, Braunwald E: Potential benefits of late reperfusion of infracted myocardium: the open artery hypothesis. Circulation 1993; 88(pt 1): 2426-2436.

  86. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-l). Lancet 1995; 345: 686-687.

  87. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.

  88. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J; EPHESUS Investigators: Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425-431.

  89. Early treatment of unstable angina in the coronary care unit: a randomized, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both: report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 1986; 56: 400-413.

  90. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-528.




2020     |     www.medigraphic.com